J7513 is a valid 2023 HCPCS Code that could be used to indicate Daclizumab, parenteral, 25 mg for reimbursement purposes.
J7513 belongs to Medical Care Type of Service and has been in effect since Jan 01, 2018.
Daclizumab, parenteral
J7513 code information
| HCPCS code: | J7513 |
| Description: | DACLIZUMAB, PARENTERAL, 25 MG |
| Effective Date: | Jan 01, 2018 |
| Added Date: | Jan 01, 1999 |
| Termination Date: | HCPCS J7513 was terminated on Nov 30, -0001 |
| Pricing indicator: | 51 - DRUGS |
| Multi Pricing indicator: | A - NOT APPLICABLE AS HCPCS PRICED UNDER ONE METHODOLOGY |
| Coverage code: | D - SPECIAL COVERAGE INSTRUCTIONS APPLY |
| BETOS code: | O1E - OTHER DRUGS |
| Action code: | N - NO MAINTENANCE FOR THIS CODE |
| Type of Service: |
1 - MEDICAL CARE
G - IMMUNOSUPPRESSIVE DRUGS
|
| Anesthesia BUQ: | 0 |
Below a selection of HCPCS codes related to J7513